Catalyst Pharmaceuticals Inc (CPRX.O) Key Developments | Reuters.com
Edition:
United States

Catalyst Pharmaceuticals Inc (CPRX.O)

CPRX.O on Consolidated Issue listed on NASDAQ Capital Market

0.79USD
24 Jun 2016
Change (% chg)

$-0.09 (-9.77%)
Prev Close
$0.88
Open
$0.79
Day's High
$0.86
Day's Low
$0.75
Volume
8,328,270
Avg. Vol
1,198,292
52-wk High
$5.80
52-wk Low
$0.51

Latest Key Developments (Source: Significant Developments)

Catalyst Pharmaceuticals Partners Inc announces positive top-line Phase 3 data from Pivotal Firdapse clinical trial
Monday, 29 Sep 2014 04:03pm EDT 

Catalyst Pharmaceuticals Partners Inc:Says positive top-line results from the pivotal Phase 3 clinical trial of Firdapse (amifampridine phosphate tablets equivalent to 10 mg amifampridine) for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS).Both co-primary endpoints, quantitative myasthenia gravis score (QMG) and subject global impression (SGI), demonstrated that Firdapse was significantly superior to placebo, as did a secondary endpoint for the physician's clinical global impression of improvement.  Full Article

Catalyst Pharmaceutical Partners Initiates Phase 1(b) Safety and Tolerance Study for CPP-115
Tuesday, 2 Sep 2014 08:03am EDT 

Catalyst Pharmaceutical Partners Inc:Says initiation of its second Phase 1 safety and tolerance study for CPP-115, a novel GABA aminotransferase (GABA-AT) inhibitor.Phase 1(b) trial is designed in 2 parts to evaluate the safety and tolerability of single and multiple doses of CPP-115, including CNS side effects, and respiratory and cardiovascular safety.  Full Article

BRIEF-Catalyst Pharma finalizes late-stage trial design with FDA for Firdapse

* Catalyst Pharmaceuticals announces agreement with FDA on confirmatory phase 3 study protocol for Firdapse in Lambert-Eaton Myasthenic Syndrome